Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The CONQUER Trial
NCT06874946Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, CAR-T Cells, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Autologous CD5 CAR T-cells in t-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma, sponsored by Peking University People's Hospital. Primary endpoints: Dose-Limiting Toxicity at 28 days and Overall Response Rate at 3 months. Started Feb 2025; status: recruiting.
02
Drugs
Autologous CD5 CAR T-cells
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T-cell lymphoma
Beyond the preview
Go deeper on NCT06874946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06874946.